Companies featured in this edition of the newsletter: ACTC, CHIP, CVM, DKAM, ENZ, IWEB, MBCI, MFGD, PHC

Markets rebounded last week, on the strength of upbeat productivity and manufacturing reports that led to solid gains in all of the major indices. Despite news that the unemployment rate had hit its highest levels in 25 years, the Dow managed to end the week up 310 points, gaining 3.2% on the week to close at 10,023, up 14.2% on the year. The Nasdaq posted a gain of 3.3%, closing at 2112 and extending its yearly gains to 34%, while the S&P 500 and Russell 2000 advanced 3.2% and 3.1% respectively on the week to bring their YTD performance to 18.4% and 16.2%.

Several better than expected economic reports provided buying incentive throughout much of the week, as investors managed to shake off the previous week’s negative bias to send indices into positive territory

...

On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

...

Becton, Dickinson and Company (BDX) is set to acquire HandyLab Inc., an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The acquisition is expected to close by the year end. Financial terms of the deal have not been disclosed. Becton had already entered into a development and distribution agreement with HandyLab in May 2009. The acquisition thus enables Becton to support its molecular diagnostics strategy by accessing the HandyLab instrumentation technology, which is considered to be an industry leading molecular diagnostic automation platform. Becton plans to utilize its BD GeneOhm molecular assays onto the HandyLab platform and market it as the new BD Max system. The acquisition will boost demand for Becton’s molecular diagnostic products that will eventually drive the company’s top-line. Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The ...

Becton, Dickinson and Co. (BDX) announced that it received Food and Drug Administration (FDA) approval to market its blood collection device, BD Vacutainer Rapid Serum Tube, in the U.S. Unlike standard tubes, the Serum tubes are ready for analysis in five minutes.

The Serum tube contains a gel additive that speeds up the clotting process, thereby enabling the tube to be put in a centrifuge for analysis five minutes after it is filled. On the other hand, standard tubes require 30 minutes of clotting before they are ready for use. 

The new approval would boost demand for Serum tubes that will eventually drive revenues for the BD Diagnostics segment. BD Diagnostics is one of the three Becton’s operating segments that manufacture Serum tubes. Becton’s other two operating segments are: BD Medical and BD Biosciences.

Becton develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a

...

Corgenix Medical Corporation (CONX) Reports Loss for Year

Corgenix Medical Corporation reported a net loss of $1.57 million, or $0.05 per share, for fiscal year 2009. Revenues were $8.06 million for the year, down from $8.35 million reported last year.

Despite the loss, the results were a slight improvement over the fiscal 2008 when Corgenix Medical Corporation lost $2.1 million, or $0.06 per share. The company ended the fiscal year with $785,000 in cash, against long term debt of $744,000.

The company blamed the results on the impact of the recession on its customers. “We were obviously disappointed with the decline in revenue,” said Douglass Simpson, the CEO of Corgenix. “In addition to the reduction of revenues from our contract manufacturing sector as previously reported, much of this was due to the impact of the overall global economy on our customers around the world as they tightened their expenditures and

...

Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

...

Becton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs for use in national flu pandemic preparedness efforts. The order, worth approximately $52 million, is effective through March 2010. The new contract is part of the company’s effort to protect Americans from the H1N1 influenza virus, commonly known as "swine flu." Becton is also in constant touch with governments and vaccine companies across the globe to meet their needs during the flu season. We think that the new contract will boost Becton’s top-line. This will also add to the company’s contribution to social welfare. Becton, Dickinson and Co. develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader ...

The Cooper Companies Inc. (COO) reported fiscal third-quarter results yesterday after market close. The company posted GAAP earnings of $21.9 million or 48 cents per share, compared to $17.9 million or 39 cents per share in the year-ago period. Excluding restructuring charges, pro forma earnings per share came in at 54 cents, which missed the Zacks Consensus Estimate by nearly 13%, or 8 cents. Cooper manufactures and markets specialty healthcare products through its CooperVision and CooperSurgical units. CooperVision makes contact lenses to correct visual defects. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women's healthcare market. The company has manufacturing facilities in the U.S., U.K., Australia and Spain. The Pleasanton, CA-based company posted a 2% year-over-year growth in sales to $285.2 million. CooperVision unit’s revenue grew 2% year over year to $240.9 million driven by a 7% and 8% growth in multifocal and single-use ...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Friday August 28, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Thursday August 27, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...